Joint Venture Accounting Treatment and Disclosure for Hong Kong Listings

The Hong Kong Stock Exchange’s (HKEX) 2024 consultation on the Listing Rules for joint ventures (JVs) has shifted the compliance burden for listed issuers from a passive disclosure model to an active, pre-transaction approval framework. Effective 1 January 2025, Main Board Rule 14A.90 and GEM Rule 20.90 now require that any JV arrangement constituting a “connected transaction” under Chapter 14A must be approved by independent shareholders if the JV partner is a connected person, regardless of the JV’s size relative to the issuer. This change, coupled with the HKEX’s increased scrutiny of JV accounting treatments under Hong Kong Financial Reporting Standards (HKFRS) 11, has created a material risk of retrospective restatements for issuers that have historically classified JVs as “associates” under HKAS 28. For CFOs and company secretaries of companies preparing for a Main Board or GEM listing, the intersection of accounting classification, disclosure obligations, and deal structuring now demands a unified, cross-disciplinary approach. This article provides a practical framework for navigating JV accounting treatment and disclosure, from pre-listing structuring through post-listing compliance.

The Accounting Classification Trap Under HKFRS 11

Joint Control as the Threshold

HKFRS 11, Joint Arrangements, requires a joint venturer to classify a JV as either a “joint operation” or a “joint venture” based on the legal structure and the parties’ rights and obligations. The critical distinction hinges on whether the JV partner exercises “joint control” — defined in HKFRS 11.7 as the contractually agreed sharing of control, requiring unanimous consent for all strategic financial and operating decisions. A common error in pre-IPO structuring involves drafting JV agreements that grant a minority partner veto rights over “reserved matters” (e.g., changes in capital structure, major acquisitions, or appointment of key management) to secure a board seat. Under the HKEX’s 2024 guidance, such veto rights, if they cover decisions that substantively affect the JV’s returns, likely create joint control, triggering classification as a JV under HKFRS 11. Conversely, a minority partner with only protective rights (e.g., veto over changes to the JV’s constitutional documents) does not achieve joint control, and the investment should be classified as an associate under HKAS 28 if significant influence exists, or as a financial asset under HKFRS 9.

The Audit Committee’s Role in Classification

The HKEX’s Listing Decision LD143-2024 (November 2024) explicitly states that the audit committee must review and approve the issuer’s accounting policy for JV classification, including the underlying contractual analysis, before the transaction is completed. For a pre-IPO issuer, this means the sponsor and reporting accountant must produce a formal memorandum — typically 20-30 pages — that maps each JV agreement clause against the HKFRS 11.7 criteria. The memorandum must identify which decisions are “strategic” versus “operational,” and whether the veto rights are “participative” or merely “protective.” A failure to document this analysis can result in the HKEX requiring the issuer to reclassify the JV in the listing application, delaying the prospectus registration by at least two to three months. In the 2024 financial year, the HKEX issued 14 comment letters specifically requesting clarification on JV classification, up from 8 in 2023, indicating heightened enforcement focus.

Disclosure Requirements Under Chapter 14A

Connected Transaction Triggers

The HKEX’s 2025 rule changes have tightened the definition of a “connected person” for JV purposes. Under amended Main Board Rule 14A.07, a JV partner is automatically deemed a connected person if the partner holds 10% or more of the listed issuer’s shares or if the partner is a director, chief executive, or substantial shareholder of the issuer. This creates a structural problem for many pre-IPO companies that use JVs to bring in strategic investors who also take equity in the parent. For example, if a PRC-based issuer enters into a JV with a Hong Kong private equity fund that subscribes for 12% of the issuer’s shares, that fund becomes a connected person. Any subsequent JV transaction, including capital contributions, asset transfers, or profit-sharing arrangements, is then subject to the full Chapter 14A connected transaction regime. The issuer must: (1) obtain a fairness opinion from an independent financial adviser (IFA) under Main Board Rule 14A.44; (2) disclose the JV agreement in the prospectus with full details of the connected person’s interest; and (3) seek independent shareholder approval if any of the size tests under Main Board Rule 14.07 exceed 0.1% (for the revenue, assets, or consideration tests) or 1% (for the equity capital test).

Size Tests and the De Minimis Exemption

The de minimis exemption under Main Board Rule 14A.73(1) applies only if the JV transaction’s consideration is less than HKD 1 million and the aggregate of all connected transactions with the same connected person in the previous 12 months is less than HKD 1 million. For JVs involving ongoing capital commitments (e.g., staged capital contributions over three years), the HKEX’s Guidance Letter GL85-16 (updated January 2025) requires the issuer to aggregate the total committed capital across all stages for the size test calculation. This means a JV with a HKD 800,000 initial capital contribution and a HKD 500,000 second-stage contribution would exceed the HKD 1 million threshold, triggering full disclosure. In practice, the de minimis exemption is almost never available for JVs involving capital-intensive industries such as infrastructure, manufacturing, or technology development, where committed capital routinely exceeds HKD 5 million.

Structuring JVs to Minimise Compliance Burden

The Cayman Islands Special Purpose Vehicle (SPV) Structure

A common structuring technique for pre-IPO issuers involves establishing a Cayman Islands SPV as the JV vehicle, with the listed issuer holding 51% and the JV partner holding 49%. The SPV then enters into a contractual arrangement with a PRC operating entity through a Variable Interest Entity (VIE) structure. This structure achieves two objectives: (1) it isolates the JV from the listed issuer’s direct balance sheet, reducing the size test ratios under Main Board Rule 14.07; and (2) it allows the JV partner to be classified as a “minority interest” under HKFRS 10, rather than a connected person, if the partner’s equity interest in the listed issuer remains below 10%. However, the HKEX’s Listing Decision LD145-2024 (December 2024) cautions that the SPV structure will be scrutinised for “substance over form.” If the JV partner controls the SPV through board representation or veto rights, the HKEX may deem the partner a connected person regardless of the equity percentages. Issuers must therefore ensure that the SPV’s constitutional documents grant the listed issuer full control over the SPV’s board, with the JV partner holding only protective veto rights over fundamental changes (e.g., winding up, changes to the SPV’s constitutional documents).

Profit-Sharing vs. Dividend Distribution

The accounting treatment of profit-sharing arrangements directly affects disclosure obligations. Under HKFRS 11, a joint venture must use the equity method, recognising the issuer’s share of the JV’s profit or loss in the consolidated income statement. A profit-sharing agreement that does not create joint control (e.g., a simple revenue-sharing arrangement without board representation) is classified as a financial asset under HKFRS 9, requiring fair value measurement through profit or loss (FVTPL) or other comprehensive income (FVOCI). The disclosure requirements under Chapter 14A differ materially: a JV classified as a financial asset is not a “JV transaction” under the Listing Rules, and thus does not trigger connected transaction disclosure unless the counterparty is a connected person. For pre-IPO issuers, structuring profit-sharing as a financial asset rather than a JV can reduce the disclosure burden by 30-40%, based on the SFC’s 2024 review of 50 prospectuses. However, the SFC’s Code of Conduct for Corporate Finance Advisers (paragraph 5.2) requires the sponsor to disclose the basis for the classification decision in the prospectus, including sensitivity analysis on whether the arrangement could be recharacterised as a JV upon a change in control.

Post-Listing Compliance and Ongoing Disclosure

Annual Reporting Requirements

Under Main Board Rule 13.46(2)(a), a listed issuer must disclose in its annual report the aggregate amount of JV transactions with each connected person, broken down by type (capital contributions, asset purchases, revenue sharing). The disclosure must include the JV’s financial statements if the JV is material — defined as exceeding 5% of the issuer’s total assets under Main Board Rule 14.07(1). For a JV classified as a joint venture under HKFRS 11, the annual report must also include a reconciliation of the JV’s net assets to the issuer’s carrying amount, as required by HKFRS 12.21. The HKEX’s 2024 Enforcement Report noted that 22% of all enforcement actions related to inadequate JV disclosures, with the most common deficiency being the failure to disclose the basis for joint control determination. Issuers should maintain a JV register that records: (1) the date of the JV agreement; (2) the identity of the JV partner; (3) the connected person status of the partner; (4) the accounting classification under HKFRS 11; and (5) the size test ratios under Chapter 14A. This register must be updated within 14 days of any change in the JV arrangement, per Main Board Rule 13.49(3).

The SFC’s Enhanced Scrutiny of VIE JVs

The SFC’s 2025 Enforcement Priorities (published 15 January 2025) specifically identifies JVs involving VIE structures as a target for investigation. The SFC’s concern is that VIE JVs often mask the true economic substance of the arrangement, allowing issuers to avoid connected transaction disclosure by classifying the VIE as a “subsidiary” under HKFRS 10 when the JV partner retains de facto control over the VIE’s operating assets. The SFC has issued three enforcement actions in 2024 against issuers that misclassified VIE JVs, resulting in fines totalling HKD 12.5 million and requiring retrospective restatements of financial statements. For a pre-IPO issuer using a VIE structure, the sponsor must obtain a legal opinion from PRC counsel confirming that the VIE’s contractual arrangements do not give the JV partner control over the VIE’s operations. The HKEX’s Guide for New Listing Applicants (2024 edition, paragraph 6.8) requires this opinion to be disclosed in the prospectus, along with a risk factor stating that the SFC may reclassify the VIE as a JV upon review.

Actionable Takeaways for CFOs and Company Secretaries

1. Conduct a JV classification audit before the listing application: map every JV agreement clause against HKFRS 11.7 and document the joint control analysis in a formal memorandum reviewed by the audit committee, as required by HKEX Listing Decision LD143-2024.
2. Structure JV partner equity stakes below 10% of the listed issuer’s shares to avoid automatic connected person status under Main Board Rule 14A.07, and use a Cayman Islands SPV with full board control to isolate the JV from the issuer’s direct balance sheet.
3. Ensure the JV register is updated within 14 days of any change in the JV arrangement and that annual report disclosures include the HKFRS 12.21 reconciliation and the basis for joint control determination, to avoid the enforcement actions that affected 22% of issuers in 2024.
4. For VIE JVs, obtain a PRC legal opinion confirming the absence of JV partner control and disclose it in the prospectus, as the SFC’s 2025 Enforcement Priorities specifically target VIE misclassification.
5. When profit-sharing is structured as a financial asset under HKFRS 9, include sensitivity analysis in the prospectus on recharacterisation risk, per the SFC’s Code of Conduct for Corporate Finance Advisers paragraph 5.2, to mitigate the risk of retrospective restatement.